Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03000660 · ClinicalTrials.gov registry record · Phase 1
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
A Phase 1 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03000660 is a Phase 1 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT03000660, a Phase 1 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a study to determine the safety, tolerability and maximum tolerated dose of Venetoclax (ABT-199) and dexamethasone in relapsed or refractory amyloid light chain (AL) amyloidosis patients.
Interventions
- DRUG Venetoclax
- DRUG Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03000660
The ClinicalTrials.gov registry entry for NCT03000660 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venetoclax is the first listed.
NCT03000660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03000660 about?
NCT03000660 is a clinical study titled "Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis". This is a study to determine the safety, tolerability and maximum tolerated dose of Venetoclax (ABT-199) and dexamethasone in relapsed or refractory amyloid light chain (AL) amyloidosis patients.
What is the current status of trial NCT03000660?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-01. Estimated completion is 2019-10-10.
What interventions are being tested in trial NCT03000660?
The interventions under investigation include: Venetoclax (DRUG), Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT03000660?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.